Navigation Links
DrugRisk Update: New Study Warns of Cancer in Byetta Side Effects
Date:5/4/2013

Los Angeles, CA (PRWEB) May 04, 2013

The diabetes drug safety advocates at DrugRisk.com are announcing updated information for patients who have taken the medication Byetta. A recent study suggests the drug may have higher occurrence rates of pancreatic cancer and thyroid cancer than traditional treatments.

DrugRisk was created to improve the safety of those taking popular prescription drugs by providing the latest warnings, recalls, studies and legal news. Patients can see if others are experiencing similar side effects and decide if they need legal advice.

Byetta is a twice-daily injectable medication released in 2005 to help those with type-2 diabetes control blood sugar. It generated sales of over $300 million last year, when it was purchased with Amylin Pharmaceuticals by Bristol-Myers Squibb*.

However, DrugRisk has added a 2011 study from UCLA indicating Byetta could increase the risk of pancreatic cancer by 290% and thyroid cancer by 473%**. The Journal for the American Medical Association also recently published findings showing these drugs can double the risk of pancreatitis, a major risk factor for pancreatic cancer***.

Now, DrugRisk has added a new report by the Institute for Safe Medication Practices, which found in an analysis of FDA reports that patients were over 20 times as likely to report pancreatitis, pancreatic cancer or thyroid cancer from Januvia than from traditional diabetes treatment like metformin****.

Due to the number of patients filing a Byetta lawsuit alleging cancer, lawyers have asked that cases be consolidated to a special federal multi-district court in California****. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452, United States Judicial Panel on Multidistrict Litigation).

Anyone affected by cancer after taking Byetta is encouraged to speak with a lawyer about their legal options. However, due to the specialized nature of federal drug injury cases, DrugRisk only recommends lawyers who have already handled Byetta lawsuits.

For more information on the research, side effects and litigation news related to Byetta and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.

*Bloomberg, 2/25/13; bloomberg.com/news/2013-02-25/merck-bristol-diabetes-drugs-linked-to-pancreatitis-risk.html
**Gastroenterology, July 2011; ctsi.ucla.edu/education/files/publicview/training/docs/FDA-analysis.pdf
***JAMA Internal Medicine, 2/25/13; archinte.jamanetwork.com/article.aspx?articleid=1656537
****Institute for Safe Medication Practices, 4/18/13; ismp.org/QuarterWatch/pdfs/2012Q3.pdf
*****JPML, 4/5/13; cdn.aboutlawsuits.com/wp-content/uploads/2013-04-05-Incretin-Mimetics-MDL.pdf

Read the full story at http://www.prweb.com/releases/byetta-lawsuit/side-effects/prweb10699747.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisk Adds New Pancreatic Cancer Warning for Diabetes Drug Januvia
2. DrugRisks News Update: Bayer Loses Yaz Patent as Blood Clot Settlements Continue
3. DrugRisk Update: Court Asks for Pradaxa Lawsuit Test Cases
4. DrugRisks Adds Update From Court Ordering Mediation of Stryker Hip Lawsuits
5. DrugRisk Announces Launch of Byetta Cancer Resource Center
6. DrugRisks Update: Federal Court Schedules First Mirena Lawsuit Hearing
7. DrugRisk Announces Addition of Januvia Cancer Resource Center
8. DrugRisks Legal Update: Jury to Decide Actos Cancer Trial This Week
9. DrugRisks Update: Doctor Testifies Actos Main Cause of Bladder Cancer in Trial
10. DrugRisk Announces Launch of DePuy Hip Resource Center
11. DrugRisk Update: Mirena Maker Asks to Keep Lawsuits With Local Court, Judge
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... As health ... medicine known as “patient engagement.” The patient is doing more than filling out a ... , “There is an increasing emphasis in health care and research on the ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along ... updates for the primary prevention of cardiovascular diseases during the 15th Annual ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Ellevate Network, ... in business to advocate for action towards gender equality at their inaugural Summit in ... around the globe, and reached a social audience of over 3 million. To watch ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “The Journey: From ... every danger possible to save lost souls in the Philippines. “The Journey: From the ... is a dedicated teacher of the Bible. She has taught all ages and currently ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... Oct. 12, 2017 AVACEN Medical , Inc. ... with their  2017 New Product Innovation Award for Its ... primary and secondary medical device market research by Frost & ... first-to-market OTC, drug-free pain relief product, the AVACEN 100, offers ... treating fibromyalgia widespread pain. ...
(Date:10/12/2017)... , Oct. 12, 2017 West Pharmaceutical ... innovative solutions for injectable drug administration, today announced that ... market opens on Thursday, October 26, 2017, and will ... and business expectations at 9:00 a.m. Eastern Time. To ... 253-336-8738 (International). The conference ID is 94093362. ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ... on fulfilling the promise of precision medicine, today announced ... joined Caris, Precision Oncology Alliance™ (POA) as its 17 ... centers, the St. Jude Crosson Cancer Institute will help ... the use of tumor profiling, making cancer treatment more ...
Breaking Medicine Technology: